Literature DB >> 34383953

Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction.

Ian A Strohbehn1, Sarah Street2, Donald Chute1, Harish Seethapathy1, Meghan Lee1, Rituvanthikaa Seethapathy1, Zsofia D Drobni3,4, Osama Rahma5, Tomas G Neilan3,6, Leyre Zubiri7, Kerry Reynolds7, Meghan E Sise1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34383953      PMCID： PMC8719582          DOI： 10.1093/ndt/gfab240

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   7.186


× No keyword cloud information.
  11 in total

1.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

2.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.

Authors:  Linda E Lévesque; James A Hanley; Abbas Kezouh; Samy Suissa
Journal:  BMJ       Date:  2010-03-12

3.  Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Authors:  Priyanka C Iyer; Maria E Cabanillas; Steven G Waguespack; Mimi I Hu; Sonali Thosani; Victor R Lavis; Naifa L Busaidy; Sumit K Subudhi; Adi Diab; Ramona Dadu
Journal:  Thyroid       Date:  2018-10       Impact factor: 6.568

4.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 5.  Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.

Authors:  Mario Sznol; Michael A Postow; Marianne J Davies; Anna C Pavlick; Elizabeth R Plimack; Montaser Shaheen; Colleen Veloski; Caroline Robert
Journal:  Cancer Treat Rev       Date:  2017-06-22       Impact factor: 12.111

6.  Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.

Authors:  Danae A Delivanis; Michael P Gustafson; Svetlana Bornschlegl; Michele M Merten; Lisa Kottschade; Sarah Withers; Allan B Dietz; Mabel Ryder
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

7.  Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.

Authors:  Harish Seethapathy; Sophia Zhao; Ian A Strohbehn; Meghan Lee; Donald F Chute; Halla Bates; Gabriel E Molina; Leyre Zubiri; Shruti Gupta; Shveta Motwani; David E Leaf; Ryan J Sullivan; Osama Rahma; Kimberly G Blumenthal; Alexandra-Chloe Villani; Kerry L Reynolds; Meghan E Sise
Journal:  Kidney Int Rep       Date:  2020-07-21

8.  The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Harish Seethapathy; Sophia Zhao; Donald F Chute; Leyre Zubiri; Yaa Oppong; Ian Strohbehn; Frank B Cortazar; David E Leaf; Meghan J Mooradian; Alexandra-Chloé Villani; Ryan J Sullivan; Kerry Reynolds; Meghan E Sise
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-31       Impact factor: 8.237

9.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Authors:  Omar Mamlouk; Umut Selamet; Shana Machado; Maen Abdelrahim; William F Glass; Amanda Tchakarov; Lillian Gaber; Amit Lahoti; Biruh Workeneh; Sheldon Chen; Jamie Lin; Noha Abdel-Wahab; Jean Tayar; Huifang Lu; Maria Suarez-Almazor; Nizar Tannir; Cassian Yee; Adi Diab; Ala Abudayyeh
Journal:  J Immunother Cancer       Date:  2019-01-06       Impact factor: 13.751

10.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

Authors:  Frank B Cortazar; Zoe A Kibbelaar; Ilya G Glezerman; Ala Abudayyeh; Omar Mamlouk; Shveta S Motwani; Naoka Murakami; Sandra M Herrmann; Sandhya Manohar; Anushree C Shirali; Abhijat Kitchlu; Shayan Shirazian; Amer Assal; Anitha Vijayan; Amanda DeMauro Renaghan; David I Ortiz-Melo; Sunil Rangarajan; A Bilal Malik; Jonathan J Hogan; Alex R Dinh; Daniel Sanghoon Shin; Kristen A Marrone; Zain Mithani; Douglas B Johnson; Afrooz Hosseini; Deekchha Uprety; Shreyak Sharma; Shruti Gupta; Kerry L Reynolds; Meghan E Sise; David E Leaf
Journal:  J Am Soc Nephrol       Date:  2020-01-02       Impact factor: 10.121
View more
  1 in total

1.  Hypothyroidism-induced kidney dysfunction: an under-recognized phenomenon in patients on immune checkpoint inhibitors.

Authors:  Hui Zhuan Tan; Ling Zhu; Jack Junjie Chan; Tanujaa D/O Rajasekaran; Jason Chon Jun Choo
Journal:  Clin Kidney J       Date:  2022-02-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.